Screening of thiosemicarbazones as antimycotic drugs

Fungal infections have become a problem of increasing importance over the past last decades, especially in patients with immunological impairment, due to HIV infections, organ transplantations or cancer therapy. The most frequently diagnosed fungal infections are caused by pathogens of the genera Candida, Cryptococcus and Aspergillus. Current treatments use a limited number of antifungal drugs and the increased resistance to these molecules is now a great problem in medicine. Is then important to select and develop new antifungal therapeutics. Thiosemicarbazones have received great interest because of their chemical and biological activities, such as antibacterial, antivirus, antiamoebic, and antitumor activities in human pharmacology. In order to test if an antifungal activity is associated to some of these molecules we screened 16 different thiosemicarbazone molecules, against a panel of fungal pathogens. Two of these compounds showed interesting activity. Results will be here presented.